Table 1.
Characteristics of SARS-CoV-2 infection individuals for the main analyses.
| Total (N = 14,991) | Median time to viral shedding, day (IQR) | 7-day cumulative viral shedding rate, % (95%CI) | 14-day cumulative viral shedding rate, % (95%CI) | |
|---|---|---|---|---|
| Characteristics | ||||
| Age group - no. (%) | ||||
| 3–17 years | 731 (4.9) | 11 (8–13) | 18.5 (15.6–21.2) | 84.4 (81.5–86.8) |
| 18–39 years | 4420 (29.5) | 11 (8–14) | 21.5 (20.2–22.7) | 81.4 (80.2–82.5) |
| 40–59 years | 4998 (33.3) | 11 (8–14) | 21.4 (20.2–22.5) | 75.7 (74.5–76.9) |
| 60–79 years | 3529 (23.5) | 13 (9–16) | 17.5 (16.2–18.7) | 61.4 (59.7–62.9) |
| ≥80 years | 1313 (8.8) | 16 (11–20) | 14.3 (12.4–16.2) | 42.0 (39.2–44.6) |
| Gender - no. (%) | ||||
| Female | 7458 (49.7) | 12 (9–15) | 18.2 (17.3–19.0) | 69.6 (68.5–70.6) |
| Male | 7533 (50.3) | 11 (8–15) | 21.3 (20.4–22.2) | 73.6 (72.5–74.5) |
| With comorbidities - no. (%) | ||||
| No | 11,315 (75.5) | 11 (8–14) | 20.6 (19.9–21.3) | 20.6 (19.9–21.3) |
| Yes | 3676 (24.5) | 14 (10–17) | 17.0 (15.8–18.2) | 17.0 (15.8–18.2) |
| Vaccination status - no. (%) | ||||
| Incomplete vaccination | 4603 (30.7) | 13 (10–17) | 15.8 (14.8–16.9) | 59.5 (58.0–60.9) |
| Full vaccination | 4430 (29.6) | 11 (8–14) | 21.7 (20.5–22.9) | 75.9 (74.6–77.2) |
| Booster vaccination | 5958 (39.7) | 11 (8–14) | 21.3 (20.2–22.3) | 77.6 (76.5–78.6) |
| Admission and treatment | ||||
| Severe or critical infection - no. (%) | ||||
| No | 14,752 (98.4) | 12 (8–15) | 19.9 (19.2–20.5) | 72.2 (71.4–72.9) |
| Yes | 239 (1.6) | 18 (13–24) | 10.5 (6.5–14.4) | 31.8 (25.5–37.7) |
| Take Paxlovid within 5 days - no. (%) | ||||
| No | 14,404 (96.1) | 12 (8–15) | 19.7 (19.0–20.3) | 71.4 (70.7–72.2) |
| Yes | 587 (3.9) | 11 (8–14) | 21.3 (17.9–24.6) | 75.5 (71.7–78.7) |
IQR, interquartile range; CI, confidence interval.